In response to patient perceptions that cannabis can control some of the symptoms of multiple sclerosis (MS), scientific studies in experimental models and clinical trials in MS have been undertaken. These studies and recent understanding of the biology of the cannabinoid system and MS have provided a rationale and objective evidence to support these perceptions. Indeed, the first cannabis-based medicine for the treatment of signs has been recently licensed for use in MS. Although most clinical studies have focused on symptom control, experimental evidence also indicates a potential action for cannabinoids in the control of autoimmune and neurodegenerative processes. These drive the underlying disease pathology that cause the varied symptomatology, for which cannabis-based medicines may currently be used. In the future it may possible to harness the medical benefits that the cannabis system has to offer to control MS, whilst limiting the adverse effects, both physical and psycho-social, associated with smoking cannabis.
CITATION STYLE
Pryce, G., Jackson, S. J., & Baker, D. (2008). Cannabinoids for the control of multiple sclerosis. In Cannabinoids and the Brain (pp. 375–394). Springer US. https://doi.org/10.1007/978-0-387-74349-3_18
Mendeley helps you to discover research relevant for your work.